Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Author(s): De Flora S,  Ganchev G,  Iltcheva M,  La Maestra S,  Micale RT,  Steele VE,  Balansky R

Journal: Trends Pharmacol Sci

Date: 2016 Feb

Major Program(s) or Research Group(s): CADRG

PubMed ID: 26726119

PMC ID: PMC4728041

Abstract: Many drugs in common use possess pleiotropic properties that make them capable of interfering with carcinogenesis mechanisms. We discuss here the ability of pharmacological agents to mitigate the pulmonary carcinogenicity of mainstream cigarette smoke. The evaluated agents include anti-inflammatory drugs (budesonide, celecoxib, aspirin, naproxen, licofelone), antidiabetic drugs (metformin, pioglitazone), antineoplastic agents (lapatinib, bexarotene, vorinostat), and other drugs and supplements (phenethyl isothiocyanate, myo-inositol, N-acetylcysteine, ascorbic acid, berry extracts). These drugs have been evaluated in mouse models mimicking interventions either in current smokers or in ex-smokers, or in prenatal chemoprevention. They display a broad spectrum of activities by attenuating either smoke-induced preneoplastic lesions or benign tumors and/or malignant tumors. Together with epidemiological data, these findings provide useful information to predict the potential effects of pharmacological agents in smokers.